Why antipsychotics cause extrapyramidal symptoms and how the types differ

Explain why a psychiatric drug affects movement

Dopamine acts in several brain pathways. Blocking D2 receptors in pathways linked to psychosis is the intended therapeutic effect, but antipsychotics do not block only those receptors. The nigrostriatal pathway connects the substantia nigra to the striatum and helps regulate smooth, controlled movement. Blocking dopamine there produces movement effects similar to those of dopamine loss in Parkinson disease.

Research links acute extrapyramidal symptoms to high D2 receptor occupancy in this pathway. First-generation antipsychotics, especially high-potency agents, carry the greatest risk. Second-generation antipsychotics generally have lower affinity for D2 receptors or bind and release them differently, which may explain their lower rate of movement effects, although they can still cause them, particularly at higher doses.

Distinguish acute dystonia by its timing and look

Acute dystonia usually appears within the first few days of starting or increasing an antipsychotic. It causes sustained involuntary muscle contractions and abnormal postures, commonly affecting the head and neck. Young age, male sex and a history of substance use are recognised risk factors. The reaction can be frightening and painful, and patients may be reluctant to continue treatment afterward.

Acute dystonia responds to anticholinergic medicines, which can prevent or reverse it, given as prescribed. The nurse stays with the patient, assesses breathing and swallowing, notifies the prescriber urgently and gives the ordered treatment. Explain what happened afterward, because a patient who understands the reaction is more likely to report early signs rather than stop the medicine without telling anyone.

Separate akathisia and parkinsonism

Akathisia is an inner sense of restlessness with an urge to move, often seen as pacing, shifting from foot to foot or being unable to sit still. It usually develops within the first three months. It does not respond well to anticholinergic medicines; dose reduction, a lipid-soluble beta blocker or a benzodiazepine may be used. It can be mistaken for worsening agitation or anxiety.

Drug-induced parkinsonism develops over days to months and includes tremor, muscle rigidity and slowed movement. Older age and female sex increase the risk. Management may involve dose reduction or anticholinergic medicines, though anticholinergics are used cautiously in older adults. Tardive dyskinesia is different: it appears after months or years, causes involuntary facial and limb movements, and may persist after stopping the drug.

Turn the mechanism into nursing assessment

Assess baseline movement before treatment and watch closely after starting or increasing a dose, when acute dystonia is most likely. Ask specifically about restlessness, since patients may not volunteer it, and observe for tremor, stiffness and shuffling gait. Use structured scales for tardive dyskinesia at the intervals set by local policy. Document onset in relation to dose changes.

Report new movement symptoms to the prescriber rather than holding or changing medicines independently. Distinguish these effects from neuroleptic malignant syndrome, which combines rigidity with fever, autonomic instability and altered consciousness and needs emergency escalation. Teach patients and families which symptoms to report and reassure them that many movement effects can be treated or reduced.

Work through a hypothetical exam-style scenario

Imagine a hypothetical inpatient started on a high-potency antipsychotic three weeks ago who now paces the corridor, says he cannot sit still and feels worse inside. The options are to report increased agitation and request a higher antipsychotic dose, to give a prescribed anticholinergic for dystonia, or to assess for akathisia and report it to the prescriber. Assessing for akathisia is the strongest answer.

Reading the behaviour as worsening psychosis could lead to a dose increase that intensifies the problem, and anticholinergics are the treatment for dystonia rather than akathisia. The question tests whether timing and description point to the right extrapyramidal effect. Accurate recognition lets the prescriber choose dose reduction or another targeted treatment.

Sources and further reading

PMC: Second-generation antipsychotics and extrapyramidal adverse effects. D2 occupancy in the nigrostriatal pathway, timing, risk factors and treatment of acute dystonia, akathisia, parkinsonism and tardive dyskinesia, and lower risk with second-generation drugs.

MSD Manual Professional: Parkinson disease. Nigrostriatal dopamine depletion behind parkinsonian signs and secondary parkinsonism from basal ganglia dopamine blockade by antipsychotics.

MSD Manual Professional: Schizophrenia. Dystonia, parkinsonism, akathisia and tardive dyskinesia as antipsychotic adverse effects and lower movement disorder risk with second-generation agents.